These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31039049)

  • 21. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemostatic properties of a TFPI antibody.
    Petersen LC
    Thromb Res; 2012 May; 129 Suppl 2():S44-5. PubMed ID: 22405586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
    Monahan PE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():33-40. PubMed ID: 26637698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new era of treatment for patients with haemophilia A?
    Klamroth R
    Hamostaseologie; 2017 Aug; 37(3):216-218. PubMed ID: 27885373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative therapies for the management of inhibitors.
    Shima M; Lillicrap D; Kruse-Jarres R
    Haemophilia; 2016 Jul; 22 Suppl 5():36-41. PubMed ID: 27405674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
    Sehgal A; Barros S; Ivanciu L; Cooley B; Qin J; Racie T; Hettinger J; Carioto M; Jiang Y; Brodsky J; Prabhala H; Zhang X; Attarwala H; Hutabarat R; Foster D; Milstein S; Charisse K; Kuchimanchi S; Maier MA; Nechev L; Kandasamy P; Kel'in AV; Nair JK; Rajeev KG; Manoharan M; Meyers R; Sorensen B; Simon AR; Dargaud Y; Negrier C; Camire RM; Akinc A
    Nat Med; 2015 May; 21(5):492-7. PubMed ID: 25849132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
    Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Trends in novel treatments for hemophilia].
    Shima M
    Rinsho Ketsueki; 2016; 57(10):2259-2266. PubMed ID: 27795538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-factor replacement therapy for haemophilia: a current update.
    Franchini M; Mannucci PM
    Blood Transfus; 2018 Sep; 16(5):457-461. PubMed ID: 29517971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Therapeutic Strategies in the Treatment of Hemophilia A.
    Muczynski V; Christophe OD; Denis CV; Lenting PJ
    Semin Thromb Hemost; 2017 Sep; 43(6):581-590. PubMed ID: 28750425
    [No Abstract]   [Full Text] [Related]  

  • 33. Concizumab: a novel anti-TFPI therapeutic for hemophilia.
    Shapiro AD
    Blood Adv; 2021 Jan; 5(1):279. PubMed ID: 33570646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.
    Pasi KJ; Lissitchkov T; Mamonov V; Mant T; Timofeeva M; Bagot C; Chowdary P; Georgiev P; Gercheva-Kyuchukova L; Madigan K; Van Nguyen H; Yu Q; Mei B; Benson CC; Ragni MV
    J Thromb Haemost; 2021 Jun; 19(6):1436-1446. PubMed ID: 33587824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia.
    Tiede A
    Hamostaseologie; 2017; 37(4):307-310. PubMed ID: 29582931
    [No Abstract]   [Full Text] [Related]  

  • 36. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2017 Clinical trials update: Innovations in hemophilia therapy.
    Hartmann J; Croteau SE
    Am J Hematol; 2016 Dec; 91(12):1252-1260. PubMed ID: 27563744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.